News | August 08, 2025
Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The submission is supported by positive results from the Phase 3 AMPLIFY trial
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
cSCC is one of the most common cancers in the U.S. and globally
Subscribe To Our Newsletter & Stay Updated
